問卷

TPIDB > Principal Investigator

Principal Investigator


國立臺灣大學醫學院附設醫院雲林分院

Division of General Internal Medicine

Division of Cardiovascular Diseases

更新時間:2025-10-18

陳政瑋
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

3Cases

2025-07-01 - 2028-12-31

Phase III

Active
A randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Baxdrostat in adult subjects with primary hyperaldosteronism.
  • Condition/Disease

    - Changes in sit-and-reach systolic blood pressure (SBP) at week 8 since baseline - Subjects whose plasma renin activity (PRA) was suppressed (< 1 μg/L/h) at baseline achieved unsuppressed plasma renin activity (PRA) (≥ 1 μg/L/h) at week 8.

  • Test Drug

    Baxdrostat

Participate Sites
6Sites

Recruiting6Sites

2026-03-01 - 2031-11-10

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-12-31 - 2029-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites